{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:28:25Z","timestamp":1761920905675,"version":"3.37.3"},"reference-count":38,"publisher":"BMJ","issue":"12","funder":[{"name":"Sanofi-Genzyme","award":["GZ-2015-11423"],"award-info":[{"award-number":["GZ-2015-11423"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate potential neuroprotective and pro-remyelinating effects of alemtuzumab in multiple sclerosis (MS), using the visual pathway as a model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We monitored clinical, multifocal visual evoked potential (mfVEP) and MRI outcomes in 30 patients commencing alemtuzumab for relapsing MS, and a reference group of 20 healthy controls (HCs), over 24 months. Change in mfVEP latency was the primary endpoint; change in optic radiation (OR) lesion diffusion metrics and Mars letter contrast sensitivity over the course of the study were secondary endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In patients, we observed a mean shortening of mfVEP latency of 1.21 ms over the course of the study (95%\u2009CI 0.21 to 2.21, p=0.013), not altered by correction for age, gender, disease duration or change in OR T2 lesion volume. Mean mfVEP latency in the HC group increased over the course of the study by 0.72 ms (not significant). Analysis of chronic OR T2 lesions (patients) showed an increase in normalised fractional anisotropy and axial diffusivity between baseline and 24 months (both p&lt;0.01). Mean Mars letter contrast sensitivity was improved at 24 months vs baseline (p&lt;0.001), and driven by an early improvement, in both patients and HC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found evidence of partial lesion remyelination after alemtuzumab therapy, indicating either natural restoration in the context of a \u2018permissive\u2019 local milieu; or potentially an independent, pro-reparative mechanism of action. The visual system presents a unique opportunity to study function-structure specific effects of therapy and inform the design of future phase 2\u2009MS remyelination trials.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-326164","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T17:21:06Z","timestamp":1624987266000},"page":"1319-1324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy"],"prefix":"10.1136","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-7662","authenticated-orcid":false,"given":"Chenyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kain","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Beadnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinda","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Klistorner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-8864","authenticated-orcid":false,"given":"Michael Harry","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"2022011011051727000_92.12.1319.1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10100326"},{"key":"2022011011051727000_92.12.1319.2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304094"},{"key":"2022011011051727000_92.12.1319.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307721"},{"key":"2022011011051727000_92.12.1319.4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"2022011011051727000_92.12.1319.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354"},{"key":"2022011011051727000_92.12.1319.6","doi-asserted-by":"publisher","DOI":"10.1177\/135245859700300213"},{"key":"2022011011051727000_92.12.1319.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330203"},{"key":"2022011011051727000_92.12.1319.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.05.032"},{"key":"2022011011051727000_92.12.1319.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.12.020"},{"key":"2022011011051727000_92.12.1319.10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WCO.0000000000000334","article-title":"Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases: common and divergent pathways of tissue damage","volume":"29","author":"Barnett","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"2022011011051727000_92.12.1319.11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0140-z"},{"key":"2022011011051727000_92.12.1319.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001281"},{"key":"2022011011051727000_92.12.1319.13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cnp.2019.03.002","article-title":"The electrophysiological assessment of visual function in multiple sclerosis","volume":"4","author":"Barton","year":"2019","journal-title":"Clin Neurophysiol Pract"},{"key":"2022011011051727000_92.12.1319.14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"The Lancet Neurol"},{"key":"2022011011051727000_92.12.1319.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.1.77"},{"key":"2022011011051727000_92.12.1319.16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/01658107.2015.1074253","article-title":"Multifocal visual evoked potential (mfVEP) and Pattern-Reversal visual evoked potential changes in patients with visual pathway disorders: a case series","volume":"39","author":"Alshowaeir","year":"2015","journal-title":"Neuroophthalmology"},{"key":"2022011011051727000_92.12.1319.17","doi-asserted-by":"crossref","unstructured":"Wang C , Klistorner A , Ly L , et al . White matter tract-specific quantitative analysis in multiple sclerosis: comparison of optic radiation reconstruction techniques. PLoS One 2018;13:e0191131. doi:10.1371\/journal.pone.0191131","DOI":"10.1371\/journal.pone.0191131"},{"key":"2022011011051727000_92.12.1319.18","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007099"},{"key":"2022011011051727000_92.12.1319.19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307650"},{"key":"2022011011051727000_92.12.1319.20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s13311-017-0558-3","article-title":"Assessing repair in multiple sclerosis: outcomes for phase II clinical trials","volume":"14","author":"Sormani","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2022011011051727000_92.12.1319.21","doi-asserted-by":"crossref","unstructured":"Klistorner A , Vootakuru N , Wang C , et al . Decoding diffusivity in multiple sclerosis: analysis of optic radiation lesional and non-lesional white matter. PLoS One 2015;10:e0122114. doi:10.1371\/journal.pone.0122114","DOI":"10.1371\/journal.pone.0122114"},{"key":"2022011011051727000_92.12.1319.22","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2002.1267"},{"key":"2022011011051727000_92.12.1319.23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40263-018-0575-8","article-title":"Assessment of Opicinumab in acute optic neuritis using multifocal visual evoked potential","volume":"32","author":"Klistorner","year":"2018","journal-title":"CNS Drugs"},{"key":"2022011011051727000_92.12.1319.24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/WNP.0000000000000757","article-title":"Latency of multifocal visual evoked potential in multiple sclerosis: a visual pathway biomarker for clinical trials of remyelinating therapies","volume":"38","author":"Klistorner","year":"2021","journal-title":"J Clin Neurophysiol"},{"key":"2022011011051727000_92.12.1319.25","doi-asserted-by":"crossref","unstructured":"Wang C , Barnett MH , Yiannikas C , et al . Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e593. doi:10.1212\/NXI.0000000000000593","DOI":"10.1212\/NXI.0000000000000593"},{"key":"2022011011051727000_92.12.1319.26","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2002.1040"},{"key":"2022011011051727000_92.12.1319.27","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.21344"},{"key":"2022011011051727000_92.12.1319.28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/WNL.0000000000003694","article-title":"Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab","volume":"88","author":"Barton","year":"2017","journal-title":"Neurology"},{"key":"2022011011051727000_92.12.1319.29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the Topaz extension study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS Drugs"},{"key":"2022011011051727000_92.12.1319.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32346-2"},{"key":"2022011011051727000_92.12.1319.31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13543784.2020.1762567","article-title":"Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis","volume":"29","author":"Gingele","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"2022011011051727000_92.12.1319.32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1212\/WNL.0000000000004381","article-title":"Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?","volume":"89","author":"Wiendl","year":"2017","journal-title":"Neurology"},{"key":"2022011011051727000_92.12.1319.33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.nicl.2017.12.010","article-title":"Evidence of progressive tissue loss in the core of chronic MS lesions: a longitudinal DTI study","volume":"17","author":"Klistorner","year":"2018","journal-title":"Neuroimage"},{"key":"2022011011051727000_92.12.1319.34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/WCO.0000000000000698","article-title":"Imaging the multiple sclerosis lesion: insights into pathogenesis, progression and repair","volume":"32","author":"Wang","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2022011011051727000_92.12.1319.35","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12377"},{"key":"2022011011051727000_92.12.1319.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.06.064"},{"key":"2022011011051727000_92.12.1319.37","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.23481"},{"key":"2022011011051727000_92.12.1319.38","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020393"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-326164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T19:05:34Z","timestamp":1641841534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-326164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,11,16]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/jnnp-2021-326164"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-326164","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"type":"print","value":"0022-3050"},{"type":"electronic","value":"1468-330X"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}